Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions
- PMID: 8149659
- PMCID: PMC1534536
- DOI: 10.1111/j.1365-2249.1994.tb06244.x
Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions
Abstract
Lesions of the common inflammatory skin disease psoriasis are characterized by epidermal hyperproliferation, leucocyte adhesion molecule expression and leucocyte infiltration. The local release of proinflammatory cytokines, such as TNF-alpha, may play an important role in the induction of these events. We have, therefore, analysed aqueous extracts of lesional and uninvolved (clinically normal) stratum corneum for the presence of TNF-alpha immunoreactivity and biological activity. TNF-alpha immunoreactivity and bioactivity were consistently higher in lesional compared with uninvolved samples. By using an anti-TNF-alpha neutralizing antibody it was demonstrated that the biological activity measured was due to the presence of TNF-alpha alone. Concentrations of soluble TNF receptors (p55 and p75) were also higher in lesional stratum corneum extracts, with the p55 form predominating. The plasma of psoriatic patients was also found to contain elevated concentrations of soluble p55 compared with normal controls. These results confirm the presence of immunoreactive TNF-alpha and, for the first time, conclusively demonstrate TNF-alpha biological activity and quantifiable concentrations of soluble TNF receptors (p55 and p75) in lesional psoriatic samples. TNF-alpha recovery from stratum corneum probably reflects synthesis in deeper, viable layers, where it is likely to exert its biological effects. Local and systemic release of soluble TNF receptors, in particular p55, may serve to regulate the effects of TNF-alpha in psoriasis.
Similar articles
-
Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor.Clin Exp Immunol. 1993 Nov;94(2):354-62. doi: 10.1111/j.1365-2249.1993.tb03457.x. Clin Exp Immunol. 1993. PMID: 8222328 Free PMC article.
-
In vivo effects of cytokines on psoriatic skin grafted on nude mice: involvement of the tumour necrosis factor (TNF) receptor.Clin Exp Immunol. 1996 Oct;106(1):134-42. doi: 10.1046/j.1365-2249.1996.d01-802.x. Clin Exp Immunol. 1996. PMID: 8870711 Free PMC article.
-
Absence of tumor necrosis factor-alpha in suction blister fluids and stratum corneum from patients with psoriasis.Arch Dermatol Res. 1989;281(6):398-400. doi: 10.1007/BF00455324. Arch Dermatol Res. 1989. PMID: 2596867
-
The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.Eur Cytokine Netw. 1998 Jun;9(2):145-54. Eur Cytokine Netw. 1998. PMID: 9681390 Clinical Trial.
-
[Soluble TNF p55 and p75 receptors in the development of sepsis syndrome].Pol Merkur Lekarski. 2003 Jan;14(79):69-72. Pol Merkur Lekarski. 2003. PMID: 12712835 Review. Polish.
Cited by
-
Local versus systemic anti-tumour necrosis factor-α effects of adalimumab in rheumatoid arthritis: pharmacokinetic modelling analysis of interaction between a soluble target and a drug.Clin Pharmacokinet. 2012 Jul 1;51(7):443-55. doi: 10.2165/11599970-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22540283
-
Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment.Ann Rheum Dis. 2006 Dec;65(12):1551-7. doi: 10.1136/ard.2005.050963. Epub 2006 May 25. Ann Rheum Dis. 2006. PMID: 16728461 Free PMC article.
-
Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors.Ann Rheum Dis. 2002 Apr;61(4):298-304. doi: 10.1136/ard.61.4.298. Ann Rheum Dis. 2002. PMID: 11874829 Free PMC article. Review.
-
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis.Clin Pharmacokinet. 2024 Feb;63(2):137-153. doi: 10.1007/s40262-023-01341-4. Epub 2024 Jan 27. Clin Pharmacokinet. 2024. PMID: 38280146 Review.
-
HPV-Mediated Resistance to TNF and TRAIL Is Characterized by Global Alterations in Apoptosis Regulatory Factors, Dysregulation of Death Receptors, and Induction of ROS/RNS.Int J Mol Sci. 2019 Jan 8;20(1):198. doi: 10.3390/ijms20010198. Int J Mol Sci. 2019. PMID: 30625987 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials